Clinical trials in children - How are they implemented?

被引:3
作者
Hirtz, DG
Gilbert, PR
Terrill, CM
Buckman, SY
机构
[1] NINDS, NIH, Bethesda, MD 20892 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] US FDA, OCTAP, Div Pediat Drug Dev, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
关键词
D O I
10.1016/j.pediatrneurol.2005.09.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drug metabolism in children may differ from adults and adverse events may occur that are not predictable from the adult experience. Clinical trials of safety and efficacy are needed both for new treatments and those that may already be in use but have not been tested in infants and children. The role and responsibilities of different participants in a trial are discussed, including the steering committee, the clinical and statistical co-ordinating centers, and the data and safety monitoring board. Advantages of external vs internal pilot studies are reviewed. Information that is available on the websites of the Food and Drug Administration and the National Institute of Neurological Disorders and Stroke may be helpful to those planning clinical trials of interventions in children. (c) 2006 by Elsevier Inc. All rights reserved.
引用
收藏
页码:436 / 438
页数:3
相关论文
共 50 条
  • [21] Clinical trials of medicines in children
    Choonara, I
    BRITISH MEDICAL JOURNAL, 2000, 321 (7269) : 1093 - 1094
  • [22] Clinical trials: consent in children
    Waterhouse, T
    Pollard, A
    EXPERT REVIEW OF VACCINES, 2005, 4 (01) : 1 - 3
  • [23] How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review
    Wilson Bautista-Molano
    Victoria Navarro-Compán
    Robert B. M. Landewé
    Maarten Boers
    Jamie J. Kirkham
    Désirée van der Heijde
    Clinical Rheumatology, 2014, 33 : 1313 - 1322
  • [24] How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review
    Bautista-Molano, Wilson
    Navarro-Compan, Victoria
    Landewe, Robert B. M.
    Boers, Maarten
    Kirkham, Jamie J.
    van der Heijde, Desiree
    CLINICAL RHEUMATOLOGY, 2014, 33 (09) : 1313 - 1322
  • [25] CLINICAL TRIALS IN ADPKD-HOW TO CONDUCT GOOD CLINICAL TRIALS IN ADPKD?
    Hawley, Carmel
    NEPHROLOGY, 2021, 26 : 15 - 16
  • [26] HOW TO STANDARDIZE CLINICAL-TRIALS
    WILDE, J
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1982, 63 : 22 - 22
  • [27] How to integrate biomarkers in clinical trials
    Lynch, Thomas J.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S296 - S297
  • [28] How representative are insomnia clinical trials?
    Roehrs, T.
    Verster, J. C.
    Koshorek, G.
    Withrow, D.
    Roth, T.
    SLEEP MEDICINE, 2018, 51 : 118 - 123
  • [29] Pediatric clinical trials: How they are different
    Murphy, D
    Roberts, R
    PEDIATRIC RESEARCH, 2000, 47 (04) : 212A - 212A
  • [30] How representative are the results of clinical trials?
    Riedel, M
    Müller, N
    Zwack, P
    Strauss, A
    Möller, HJ
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 203 - 203